HIV vaccine - Biosantech

Drug Profile

HIV vaccine - Biosantech

Alternative Names: HIV-1 vaccine - Biosantech; Tat Oyi

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator CNRS; Universite de la Mediterranee
  • Developer Biosantech
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV-1 infections

Most Recent Events

  • 15 Mar 2016 Biosantech announces intention to submit MAA to European Union in second half of 2018
  • 15 Mar 2016 Biosantech plans a phase III pivotal trial for HIV-1 infections
  • 15 Mar 2016 Interim efficacy and adverse events data from a phase IIa trial in HIV-1 infections released by Biosantech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top